MedTrace Logo

Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.

NCT02644018 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2016-06-09

No results posted yet for this study

Summary

The purpose of this study is to determine whether Ingavirin ® dosed 30 mg daily is effective and safe in the treatment of influenza and other acute respiratory viral infections in the course of standard therapy in 3-6 years old patients.

Conditions

Interventions

DRUG

Imidazolyl ethanamide pentandioic acid

DRUG

placebo

Sponsors & Collaborators

  • Atlant Clinical Ltd.

    collaborator OTHER

  • Valenta Pharm JSC

    lead INDUSTRY

Principal Investigators

  • Ekaterina Zakharova, MD, PhD · Valenta Pharm JSC

  • Yuriy V. Lobzin, MD, PhD · Scientific Research Institute of Children's Infections, Federal Biomedical Agency, Saint-Petersburg, Russian Federation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02644018 on ClinicalTrials.gov